In breast cancer, the overexpression of a GSK-3β mutant acts as an inhibitor of endogenous wild-type GSK-3β protein, increases the sensitivity of breast cancer to chemotherapeutic compounds and blocks cell cycle progression [39]. Here, GSK3B is linked to breast cancer.